Sorry about AI Slob but I couldn't do better
\*\*PMV Pharmaceuticals (NASDAQ: PMVP) — Quick Overview\*\*
\*\*Company:\*\* PMV Pharmaceuticals
\*\*Ticker:\*\* PMVP (NASDAQ)
\*\*Founded:\*\* 2013
\*\*Headquarters:\*\* Princeton, New Jersey, USA
\*\*Market Cap:\*\* \\\~US$60–70 million (small-cap biotech)
\*\*Sector:\*\* Biotechnology / Precision Oncology
\*\*Focus:\*\* Developing targeted cancer drugs that restore the function of mutated \*\*p53\*\*, one of the most commonly altered genes in cancer.
\*\*Lead Product\*\*
\*\*Drug:\*\* Rezatapopt (PC14586)
\*\*Type:\*\* Oral small-molecule therapy
\*\*Target:\*\* TP53 \*\*Y220C\*\* mutation
\*\*Mechanism:\*\* Restores the mutant p53 protein so cancer cells can undergo apoptosis (cell death).
\*\*Clinical Status\*\*
\*\*Stage:\*\* Registrational Phase 2 (PYNNACLE trial)
\*\*Primary completion:\*\* Expected \*\*August 2026\*\*
\*\*Planned NDA submission:\*\* \*\*Q1 2027\*\* (if data remain positive)
\*\*Target Patients\*\*
Patients with \*\*TP53 Y220C-mutated advanced solid tumors\*\*
Includes ovarian, lung, breast, endometrial, and other cancers.
Mutation occurs in about \*\*1% of all cancers\*\*.
\*\*Investment Highlights\*\*
\*\*Pros\*\*
First-in-class approach to a historically difficult target (p53).
Encouraging Phase 2 efficacy so far.
Potential first approved therapy for TP53 Y220C cancers.
Small market cap provides substantial upside if successful.
\*\*Cons\*\*
Essentially a \*\*single-asset company\*\*.
Small target patient population compared with broader oncology drugs.
Clinical or regulatory setbacks would have a significant impact on valuation.
May require additional financing if commercialization is delayed.